Bone regeneration is a common surgical procedure in both dentistry and orthopedics. Bone is the second most transplanted tissue globally after blood. It represents a vast, fast-growing market (B$ 2,1 in 2013; B$ 2,7 in 2020) due to global aging.
Mimetis provides the medical sector with a new generation of synthetic bone graft substitutes that is biomimetic and able to interplay with the host tissue to reach clinical success.
The team is composed of opinion leaders and researchers in the fields of biomaterials for bone regeneration, dental implantology, and entrepreneurship and focuses on value creation and execution.
Mimetis is collaborating with the leading distributor in dental implantology to generate highly reliable comparative preclinical and clinical data, co-financed through an option agreement. The company counts on a disruptive 3D printing of biomimetic bone grafts scaffolds ready to launch.
Mimetis is open for investment in order to upscale its manufacturing of dental bone graft substitutes, extend its business to the orthopaedic market in Europe and emerging countries, develop a portfolio and participate to the change of paradigm in the treatment of patients with its groundbreaking technology allowing to produce patient-specific grafts by a proprietary 3D printing process.
Bone regeneration is a usual procedure in the following fields: dental, craniomaxillofacial, and orthopedics. Small bone defects regenerate naturally, while a bone graft is needed to cure larger defects. The objective of the surgery is to regenerate bone in order to recover its function, harmed by either traumatisms or disorders.
In the dental field, bone regeneration procedures are very common due to increasing access to dental implantology treatments, whose aim is to recover the function of the lost tooth using a dental implant screwed into the patient’s bone. When a tooth is lost, bone progressively resorbs due to a lack of mechanical stimuli. Bone grafts are used to regenerate the bone tissue, recover and maintain the bone level required to place a metallic dental implant and successfully recover the tooth’s function over time. Also, the same principle is used in Guided Bone Regeneration for alveolar sockets, periodontal defects, peri-implant defects, sinus lift, cysts.
In orthopaedics, bone grafts are used and needed in orthopaedics, spine, and trauma; often in combination with autologous bone. The benefits of synthetic bone grafts in orthopaedics include off-the-shelf availability, easy handling while the benefits of 4th generation synthetics include rapid osteointegration without active principles, which represents a competitive advantage from a regulatory point of view.
The number of bone regeneration treatments in Europe is growing fast:
Mimetis uses a unique technological basis allowing manufacturing of biomimetic biomaterials (4th generation) replicating the physiological processes of bone generation. Mimetis uses biomimicry to develop its portfolio:
The first biomimetic product, MimetikOss Granules, provides clinicians with superior clinical outcome compared to the bovine gold standard. At short term, bone regeneration is quicker and volume-stable while at long term, the graft is remodeled into newly formed bone. In the dental field, the two main indications are the peri-implant defect and alveolar defect:
The existing alternative solutions either harvest bone from animals, donors, from another part of the patient’s body, or are synthetic solutions. The following table summarizes the alternatives, their characteristics:
The existing solutions do not fully solve the existing problems. Among others, the most relevant unsolved problems are a lack of vascularization of the graft, lack of volume preservation when regenerating bone, composite regenerated bone (i.e. graft and newly formed bone) not allowing a safe and predictable implant placement and success; and slow or no clinical bone regeneration around the graft.
The use of autografts presents important drawbacks being the limited amount harvestable and morbidity of the extraction. The existing alternatives from human, animal or synthetic sources lack interaction between the graft and the receiving tissues. They integrate into the existing bone but do not transform over time into vascularized, newly formed bone; this being the main rationale to implant failure, volume loss and other adverse events.
Mimetis’ technology is unique, allowing obtaining 4th generation biomimetic bone grafts mimicking the physiological processes of bone formation. Mimetis introduces a new technological basis on which all the products in pipeline are based: MimetikOss Granules and MimetikOss 3D. MimetikOss is the first biomimetic 4th generation product and provides a solution to the unsolved problems in bone regeneration, combining 4 key factors identified in the dental field:
MimetikOss, presents a superior clinical result compared to the reference offer at short term (faster bone regeneration) and at long term being remodeled physiologically. For instance, in a rat calvaria vertical defect, the efficacy of MimetikOss (Green column) to regenerate bone was compared to the market leader Bio-Oss (Bovine solution, Blue column) after 4 and 8 weeks. At short time, MimetikOss was significantly faster in regenerating bone than Bio-Oss, although both solutions reached full bone regeneration at 8 weeks. This suggests earlier implant placement is possible with MimetikOss.
MimetikOss provided excellent clinical results. As an example, a clinical case of bone regeneration in the dental field is provided (peri-implant bone regeneration). The following clinical case provides an overview of the filling of a bony defect between implant and existing bone (Concavity defect, a,b). The soft tissue (Gingiva,c) and hard tissue (bone) results were excellent and provided a safe support for prosthesis placement (f).
MimetikOss 3D uses the same biomimetic basis for 3D-printing personalized grafts. The ideal tuning of the ink-based, patented process allows manufacturing customized geometries matchings the patient’s clinical needs, according the the clinicians requests.
Proof-of-concept showed positive results in veterinary and the product is integrated is being integrated in the ISO13485 regulated quality system of the company. Research is ongoing through the original research laboratory BBT-UPC and European Union grants.
According to GlobalData (Bone grafts and substitutes - Global analysis and market forecasts), 1,86 million surgeries including a bone graft were performed in 2013, globally. The total and forecast revenues are detailed:
The market drivers identified are:
The main players and competitors in the global market of bone grafting are: Ace Surgical, Biohorizons, Dentsply, Geistlich, DePuy Synthes (Johnson and Johnson), Institut Straumann, Zimmer-Biomet, Medtronic, Danaher (Nobel Biocare). Specifically, the market share of the most relevant companies are: Johnson and Johnson (23%), Stryker (14.5%), Zimmer (12.7%), Biomet (8.5%), Smith and Nephew (6.7%), Others (34.6%).
Mimetis’ closest competitors include 2 companies:
Mimetis introduces in the market a new biomimetic technological basis. While existing innovative companies, including Noraker and especially Artoss, focus on enhancing the ease of use using hydrogels and smaller particles, Mimetis changes the way biomaterials are manufactured to mimic the physiological processes and obtain, in fine naturally inspired biomaterials for bone regeneration.
Scientifically, Mimetis’ technology is unique, providing biomaterials recognized as natural bone by the patient’s bone cells.
Mimetis is a spin-off company from the Biomaterials, Biomechanics and Tissue Engineering research group of the Technical University of Catalonia (BBT-UPC, Mimetis Biomaterials).
Since 2013, the company raised 1M€ in dilutive funding and more than 1,2M€ in non-dilutive, including bank loans (200K€) and public grants from the Spanish and European institutions (1M€).
As of today, Mimetis has reached numerous milestones:
The management and board team includes: Yassine Maazouz (CEO, CTO), Maria-Pau Ginebra (President and co-founder), David Pastorino (CFO and co-founder), Carlos Aparicio (Investor, Board member), Ana Chinea (Commercial Director), Xavier Gil (Co-founder), Jaume Villanueva (Investor).
Mimetis aims at positioning as a reference provider and OEM manufacturer in the field of bone graft substitutes.
Mimetis’ ambition is to